Department of Medicine, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan.
PPAR Res. 2008;2008:879523. doi: 10.1155/2008/879523. Epub 2009 Mar 4.
Diabetic nephropathy is a leading cause of end-stage renal disease, which is increasing in incidence worldwide, despite intensive treatment approaches such as glycemic and blood pressure control in patients with diabetes mellitus. New therapeutic strategies are needed to prevent the onset of diabetic nephropathy. Peroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear transcription factors that play important roles in lipid and glucose homeostases. These agents might prevent the progression of diabetic nephropathy, since PPAR agonists improve dyslipidemia and insulin resistance. Furthermore, data from murine models suggest that PPAR agonists also have independent renoprotective effects by suppressing inflammation, oxidative stress, lipotoxicity, and activation of the renin-angiotensin system. This review summarizes data from clinical and experimental studies regarding the relationship between PPARs and diabetic nephropathy. The therapeutic potential of PPAR agonists in the treatment of diabetic nephropathy is also discussed.
糖尿病肾病是终末期肾病的主要病因，尽管在糖尿病患者中采用了强化治疗方法，如血糖和血压控制，但该病的发病率仍在全球范围内不断上升。需要新的治疗策略来预防糖尿病肾病的发生。过氧化物酶体增殖物激活受体 (PPAR) 是配体激活的核转录因子，在脂质和葡萄糖稳态中发挥重要作用。这些药物可能预防糖尿病肾病的进展，因为 PPAR 激动剂可改善血脂异常和胰岛素抵抗。此外，来自小鼠模型的数据表明，PPAR 激动剂还通过抑制炎症、氧化应激、脂毒性和肾素-血管紧张素系统的激活，具有独立的肾脏保护作用。这篇综述总结了关于 PPAR 与糖尿病肾病之间关系的临床和实验研究数据。还讨论了 PPAR 激动剂在治疗糖尿病肾病方面的治疗潜力。
